Sequential versus standard triple first-line therapy for Helicobacter pylori eradication

Area of Science:

• Gastroenterology and Infectious Diseases
• Microbiology and Immunology

Background:

• Declining efficacy of standard triple therapy (STT) for H. pylori eradication necessitates exploring alternative treatments.
• Non-bismuth quadruple sequential therapy (SEQ) is proposed as a potential first-line replacement for STT.

Purpose of the Study:

• To compare the efficacy of SEQ versus STT for H. pylori eradication through a meta-analysis of randomized controlled trials (RCTs).
• To compare the incidence of adverse effects associated with both therapies.

Main Methods:

• Bibliographical searches of electronic databases and congress abstracts up to April 2015.
• Inclusion of 44 RCTs with 12,284 participants comparing 10-day SEQ with STT (≥7 days) in H. pylori-naïve adults and children.
• Intention-to-treat eradication rates, risk differences, heterogeneity assessment (subgroup analyses), and GRADE methodology for evidence quality.

Main Results:

• SEQ demonstrated significantly higher eradication rates than STT (82% vs. 75%; RD 0.09, P < 0.001) with moderate-quality evidence.
• High heterogeneity (I²=75%) was observed; efficacy differences varied by geographic region, being greater in Europe.
• SEQ and STT showed equivalent efficacy when STT lasted 14 days; however, SEQ efficacy has declined in studies post-2008, with no superiority over 10-day STT.
• Adverse event rates were similar between SEQ and STT (20.4% vs. 19.5%) with high-quality, homogeneous evidence.

Conclusions:

• SEQ was more effective than STT prior to 2008, particularly against shorter STT durations.
• The efficacy advantage of SEQ has diminished over time, with recent studies showing no significant difference compared to 10-day STT.
• Neither SEQ nor STT consistently achieves optimal eradication rates (≥90%), suggesting a need for further treatment strategy development.